quinidine polygalacturonate
Modify Date: 2025-08-29 11:02:16
quinidine polygalacturonate structure
|
Common Name | quinidine polygalacturonate | ||
|---|---|---|---|---|
| CAS Number | 27555-34-6 | Molecular Weight | 518.556 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H34N2O9 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of quinidine polygalacturonateQuinidine polygalacturonate is an antiarrhythmic agent. Quinidine polygalacturonate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine polygalacturonate is also a K+ channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinidine polygalacturonate can be used for malaria research[1][2][3][4]. |
| Name | (9S)-6'-Methoxycinchonan-9-ol-D-galacturonic acid (1:1) |
|---|---|
| Synonym | More Synonyms |
| Description | Quinidine polygalacturonate is an antiarrhythmic agent. Quinidine polygalacturonate is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine polygalacturonate is also a K+ channel blocker with an IC50 of 19.9 μM, and can induce apoptosis. Quinidine polygalacturonate can be used for malaria research[1][2][3][4]. |
|---|---|
| Related Catalog | |
| In Vitro | Quinidine polygalacturonate shows cytotoxicity against MES-SA cells, and induces apoptosis[4]. Apoptosis Analysis[4] Cell Line: MES-SA and MESSA/DX5 cells Concentration: 10 μM Incubation Time: 24 hours Result: Increased the apoptotic portion sub-G1 DNA contents induced by paclitaxel, while paclitaxel had no effect on sub-G1 DNA contents undergoing apoptosis. Cell Cytotoxicity Assay[4] Cell Line: MES-SA and MESSA/DX5 cells Concentration: 10 μM Incubation Time: 24 hours Result: Showed cytotoxicity against MES-SA cells in a concentration-dependent manner. |
| In Vivo | Quinidine polygalacturonate shows effects on the PTZ-induced seizure threshold[5]. Animal Model: Male mice of the NMRI strain (age 5-6 weeks and weight 25-30 g)[5] Dosage: 10, 20, and 30 mg/kg Administration: Intraperitoneal injection; 10, 20, and 30 mg/kg; once Result: Increased the threshold dose for the onset to tonic hind limb extension at a dose of 30 mg/kg, compared to the saline-treated control group (p<0.05). |
| References |
| Molecular Formula | C26H34N2O9 |
|---|---|
| Molecular Weight | 518.556 |
| Exact Mass | 518.226440 |
| InChIKey | KUTGSSTVCUKONV-VAFYLWSTSA-N |
| SMILES | C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12.O=CC(O)C(O)C(O)C(O)C(=O)O |
| Cinchonan-9-ol, 6'-methoxy-, (9S)-, compd. with D-galacturonic acid (1:1) |
| (9S)-6'-Methoxycinchonan-9-ol - D-galacturonic acid (1:1) |